High Rates of Mortality During Drug-Resistant Tuberculosis Treatment Among Individuals With Diabetes Mellitus and Low Body Mass Index - Summary - MDSpire
Advertisement
High Rates of Mortality During Drug-Resistant Tuberculosis Treatment Among Individuals With Diabetes Mellitus and Low Body Mass Index
To estimate the effect of diabetes on all-cause mortality during rifampicin-resistant tuberculosis (RR-TB) treatment and assess whether this effect differs by body mass index (BMI) status.
Key Findings:
Among 345 individuals, 28% had diabetes and 18% died during treatment.
Adjusted hazard rates showed higher mortality for those with diabetes (aHR 2.05) and low BMI (aHR 2.33).
The highest mortality risk was found in individuals with both diabetes and low BMI (aHR 7.14).
Interpretation:
Diabetes significantly increases the risk of mortality during RR-TB treatment, particularly in individuals with low BMI, indicating a need for targeted interventions in this high-risk group.
Limitations:
The study was retrospective and may have unmeasured confounders.
Data was collected from a single hospital, which may limit generalizability.
Conclusion:
Diabetes and low BMI are critical factors associated with elevated mortality in RR-TB treatment, highlighting the importance of nutritional assessment and management in diabetic patients undergoing treatment.
by Lara D Veeken, Iceu D Kulsum, Bony W Lestari, Prayudi Santoso, Nanny N M Soetedjo, Raspati C Koesoemadinata, Adriana V Miranda, Wini Sukmawati, Argita D Salindri, Arto Y Soeroto, Reinout van Crevel
